E. Karampli

420 total citations
36 papers, 271 citations indexed

About

E. Karampli is a scholar working on Economics and Econometrics, General Health Professions and Epidemiology. According to data from OpenAlex, E. Karampli has authored 36 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 10 papers in General Health Professions and 7 papers in Epidemiology. Recurrent topics in E. Karampli's work include Health Systems, Economic Evaluations, Quality of Life (17 papers), Pharmaceutical Economics and Policy (5 papers) and Atrial Fibrillation Management and Outcomes (4 papers). E. Karampli is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (17 papers), Pharmaceutical Economics and Policy (5 papers) and Atrial Fibrillation Management and Outcomes (4 papers). E. Karampli collaborates with scholars based in Greece, Finland and United States. E. Karampli's co-authors include John Kyriopoulos, Kostas Athanasakis, Elpida Pavi, A. Beletsi, Ioannis Petrakis, Theodoros Dardavesis, Dimitris Zavras, Sylvia Elkhuizen, Raquel Faubel and Tom Bowen and has published in prestigious journals such as PLoS ONE, BMC Health Services Research and Diabetes Research and Clinical Practice.

In The Last Decade

E. Karampli

34 papers receiving 264 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Karampli Greece 11 90 75 33 31 27 36 271
Sherif Abaza Hungary 8 120 1.3× 53 0.7× 35 1.1× 22 0.7× 26 1.0× 29 306
Mehdi Aloosh Canada 12 53 0.6× 37 0.5× 16 0.5× 22 0.7× 33 1.2× 32 365
Göran Lönnberg Sweden 8 22 0.2× 59 0.8× 24 0.7× 71 2.3× 84 3.1× 10 386
Kari Linden Finland 9 37 0.4× 33 0.4× 73 2.2× 25 0.8× 33 1.2× 19 202
Pavithra Vijayakumar United States 8 47 0.5× 39 0.5× 19 0.6× 37 1.2× 43 1.6× 17 350
Xilin Zhou United States 9 70 0.8× 77 1.0× 24 0.7× 91 2.9× 44 1.6× 18 382
Martin Tauscher Germany 12 37 0.4× 79 1.1× 50 1.5× 48 1.5× 24 0.9× 33 329
Mark K. Meiselbach United States 11 159 1.8× 130 1.7× 19 0.6× 43 1.4× 50 1.9× 51 300
C. Patterson Canada 7 45 0.5× 116 1.5× 13 0.4× 48 1.5× 57 2.1× 11 325
Tara Kelley United States 10 81 0.9× 26 0.3× 25 0.8× 17 0.5× 20 0.7× 13 292

Countries citing papers authored by E. Karampli

Since Specialization
Citations

This map shows the geographic impact of E. Karampli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Karampli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Karampli more than expected).

Fields of papers citing papers by E. Karampli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Karampli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Karampli. The network helps show where E. Karampli may publish in the future.

Co-authorship network of co-authors of E. Karampli

This figure shows the co-authorship network connecting the top 25 collaborators of E. Karampli. A scholar is included among the top collaborators of E. Karampli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Karampli. E. Karampli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sidéris, Lucas, E. Karampli, & Kostas Athanasakis. (2025). Research on the issue of financial toxicity in cancer: A systematic review of the literature. Journal of Cancer Policy. 44. 100581–100581. 1 indexed citations
2.
Karampli, E., Georgios Mavrovounis, Ioannis Pantazopoulos, et al.. (2023). Evaluation of the Quality of Life of Patients with Myasthenia Gravis in Greece. Journal of Personalized Medicine. 13(7). 1130–1130. 3 indexed citations
3.
Konerding, Uwe, Tom Bowen, Sylvia Elkhuizen, et al.. (2020). The impact of accessibility and service quality on the frequency of patient visits to the primary diabetes care provider: results from a cross-sectional survey performed in six European countries. BMC Health Services Research. 20(1). 800–800. 4 indexed citations
4.
5.
6.
Beletsi, A., et al.. (2018). Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union. Value in Health Regional Issues. 16. 81–91. 26 indexed citations
7.
Mahdavi, Mahdi, Jan Vissers, Sylvia Elkhuizen, et al.. (2018). The relationship between context, structure, and processes with outcomes of 6 regional diabetes networks in Europe. PLoS ONE. 13(2). e0192599–e0192599. 13 indexed citations
8.
Konerding, Uwe, Tom Bowen, Sylvia Elkhuizen, et al.. (2017). The impact of travel distance, travel time and waiting time on health-related quality of life of diabetes patients: An investigation in six European countries. Diabetes Research and Clinical Practice. 126. 16–24. 11 indexed citations
9.
Athanasakis, Kostas, N. Boubouchairopoulou, E. Karampli, et al.. (2016). Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. American Journal of Cardiovascular Drugs. 17(2). 123–133. 13 indexed citations
10.
Athanasakis, Kostas, Aikaterini Bilitou, Dawn Lee, et al.. (2016). Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece. ClinicoEconomics and Outcomes Research. Volume 8. 583–590. 2 indexed citations
11.
Athanasakis, Kostas, E. Karampli, Dimitrios Tsounis, Aikaterini Bilitou, & John Kyriopoulos. (2015). Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting. Clinical Drug Investigation. 35(11). 693–705. 5 indexed citations
12.
Athanasakis, Kostas, et al.. (2014). Belimumab for the Treatment of Systemic Lupus Erythematosus (Sle) In Greece: A Cost-Effectiveness and Cost-Utility Analysis. Value in Health. 17(7). A532–A533. 5 indexed citations
13.
Tsiantou, V., et al.. (2014). Challenges and Opportunities in The Management of Chronic Diseases During The Economic Crisis In Greece: A Qualitative Approach. Value in Health. 17(7). A501–A501. 1 indexed citations
14.
Tsiantou, V., et al.. (2014). Access To Orphan Drugs In Greece During Economic Crisis. Value in Health. 17(7). A541–A541. 1 indexed citations
15.
Athanasakis, Kostas, et al.. (2013). A Cost-Of-Illness Analysis of Hepatitis C in Greece. Value in Health. 16(7). A496–A496. 4 indexed citations
16.
17.
Karampli, E., et al.. (2012). Management of atrial fibrillation in the Greek healthcare setting.. PubMed. 53(4). 273–8. 4 indexed citations
18.
Athanasakis, Kostas, et al.. (2012). Cost-Effectiveness of Varenicline Versus Bupropion, Nicotine-Replacement Therapy, and Unaided Cessation in Greece. Clinical Therapeutics. 34(8). 1803–1814. 15 indexed citations
19.
Athanasakis, Kostas, et al.. (2011). PMS19 The Economic Burden of Post-Menopausal Osteoporosis and Related Fractures in Greece. Value in Health. 14(7). A305–A305. 1 indexed citations
20.
Pavi, Elpida, et al.. (2010). Social determinants of dental health services utilisation of Greek adults.. PubMed. 27(3). 145–50. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherif Abaza Breakdown of academic impact, for papers by Mehdi Aloosh Breakdown of academic impact, for papers by Göran Lönnberg Breakdown of academic impact, for papers by Kari Linden Breakdown of academic impact, for papers by Pavithra Vijayakumar Breakdown of academic impact, for papers by Xilin Zhou Breakdown of academic impact, for papers by Martin Tauscher Breakdown of academic impact, for papers by Mark K. Meiselbach Breakdown of academic impact, for papers by C. Patterson Breakdown of academic impact, for papers by Tara Kelley
Rankless by CCL
2026